Egypt-based B2B healthtech 30Med has secured pre-seed funding for unknown value from anonymous angel investors to enable the company to get the necessary resources to develop its platform and expand its reach within the medical community.

Founded in 2023 by Ayman Ragab, 30Med is poised to revolutionise the way physicians engage with medical education. With a mission to bridge the gap between pharmaceutical companies and physicians, 30Med leverages interactive videos and conference events to showcase new medicines and facilitate ongoing learning.

“We are thrilled to announce the successful completion of our pre-seed funding round,” said Doctor Ayman Ragab, CEO of 30Med. “This milestone not only validates the importance of our mission but also enables us to accelerate our efforts in transforming medical education.

This pre-seed fund represents a vote of confidence in 30Med’s vision and potential. It provides the company with the necessary resources to further develop its platform and expand its reach within the medical community.

In addition to securing funding, 30Med has already achieved remarkable traction within the medical community. The platform boasts a substantial user base, comprising doctors who are eager to stay informed and engaged with the latest advancements in medicine and pharmaceuticals.

Furthermore, strategic partnerships with leading pharmaceutical companies in Egypt underscore 30Med’s commitment to reshaping the landscape of medical education. By providing a seamless avenue for pharmaceutical companies to showcase new medicines through interactive videos and conference events, 30Med is revolutionising the way medical information is disseminated and accessed.

As 30Med continues to grow and evolve, it remains steadfast in its mission to empower physicians to elevate their expertise and stay ahead in the dynamic world of healthcare.